BioCentury
ARTICLE | Clinical News

ISIS-PKKRx: Phase I data

March 9, 2015 7:00 AM UTC

A placebo-controlled, dose-escalation, Canadian Phase I trial in 48 healthy volunteers showed that single doses of 50-400 mg subcutaneous ISIS-PKKRx and once-weekly doses of 100-400 mg subcutaneous IS...